Gualberto, A., Hixon, M. L., Karp, D. D., Li, D., Green, S., Dolled-Filhart, M., . . . Pollak, M. N. (2012). Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Nature Publishing Group.
Chicago-stil citatGualberto, A., et al. Pre-treatment Levels of Circulating Free IGF-1 Identify NSCLC Patients Who Derive Clinical Benefit From Figitumumab. Nature Publishing Group, 2012.
MLA-referensGualberto, A., et al. Pre-treatment Levels of Circulating Free IGF-1 Identify NSCLC Patients Who Derive Clinical Benefit From Figitumumab. Nature Publishing Group, 2012.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.